Abstract
Objectives
This study evaluated the predictive role of 1D, 2D and 3D quantitative, enhancement-based MRI regarding overall survival (OS) in patients with colorectal liver metastases (CLM) following intra-arterial therapies (IAT).
Methods
This retrospective analysis included 29 patients who underwent transarterial chemoembolization (TACE) or radioembolization and received MRI within 6 weeks after therapy. Tumour response was assessed using 1D and 2D criteria (such as European Association for the Study of the Liver guidelines [EASL] and modified Response Evaluation Criteria in Solid Tumors [mRECIST]). In addition, a segmentation-based 3D quantification of overall (volumetric [v] RECIST) and enhancing lesion volume (quantitative [q] EASL) was performed on portal venous phase MRI. Accordingly, patients were classified as responders (R) and non-responders (NR). Survival was evaluated using Kaplan–Meier analysis and compared using Cox proportional hazard ratios (HR).
Results
Only enhancement-based criteria identified patients as responders. EASL and mRECIST did not predict patient survival (P = 0.27 and P = 0.44, respectively). Using uni- and multivariate analysis, qEASL was identified as the sole predictor of patient survival (9.9 months for R, 6.9 months for NR; P = 0.038; HR 0.4).
Conclusion
The ability of qEASL to predict survival early after IAT provides evidence for potential advantages of 3D quantitative tumour analysis.
Key Points
• Volumetric assessment of colorectal liver metastases after intra-arterial therapy is feasible.
• Early 3D quantitative tumour analysis after intra-arterial therapy may predict patient survival.
• Volumetric tumour response assessment shows advantages over 1D and 2D techniques.
• Enhancement-based MR response assessment is preferable to size-based measurements.
Similar content being viewed by others
References
Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128
Engstrom PF, Arnoletti JP, Benson AB 3rd et al (2009) NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw 7:778–831
Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC (2011) Colorectal liver metastases. Int J Surg Oncol 2011:285840
Cunningham D, Atkin W, Lenz HJ et al (2010) Colorectal cancer. Lancet 375:1030–1047
Memon K, Lewandowski RJ, Riaz A, Salem R (2012) Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies. Curr Treat Options Oncol 13:403–415
Albert M, Kiefer MV, Sun W et al (2011) Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 117:343–352
Benson AB 3rd, Geschwind JF, Mulcahy MF et al (2013) Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 49:3122–3130
Hong K, McBride JD, Georgiades CS et al (2009) Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 20:360–367
Kemeny NE, Niedzwiecki D, Hollis DR et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:1395–1403
Gonzalez-Guindalini FD, Botelho MP, Harmath CB et al (2013) Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics 33:1781–1800
Laubender RP, Lynghjem J, D'Anastasi M et al (2014) Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm. Eur Radiol 24:1521–1528
Huppert P, Wenzel T, Wietholtz H (2014) Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol 37:154–164
Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G (2013) Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 33:2077–2083
Tohme S, Sukato D, Nace GW et al (2014) Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. HPB (Oxford). doi:10.1111/hpb.12307
Egger ME, Cannon RM, Metzger TL et al (2013) Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 216:845–856, discussion 856–847
Akhlaghpoor S, Aziz-Ahari A, Amoui M, Tolooee S, Poorbeigi H, Sheybani S (2012) Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. World J Gastroenterol 18:5249–5259
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430
Janne d'Othee B, Sofocleous CT, Hanna N et al (2012) Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel. J Vasc Interv Radiol 23:153–163
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60
Riaz A, Memon K, Miller FH et al (2011) Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 54:695–704
Bonekamp D, Bonekamp S, Halappa VG et al (2013) Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. doi:10.1016/j.ejrad.2013.11.016
Heijmen L, Ter Voert EE, Nagtegaal ID et al (2013) Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol 23:748–756
Tam HH, Collins DJ, Brown G et al (2013) The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. Br J Radiol 86:20130281
Lin M, Pellerin O, Bhagat N et al (2012) Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vasc Interv Radiol 23:1629–1637
Mitchell DG, Bruix J, Sherman M, Sirlin CB (2014) LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, consensus of the LI-RADS Management Working Group and future directions. Hepatology. doi:10.1002/hep.27304
Santillan CS, Tang A, Cruite I, Shah A, Sirlin CB (2014) Understanding LI-RADS: a primer for practical use. Magn Reson Imaging Clin N Am 22:337–352
Bogaerts J, Ford R, Sargent D et al (2009) Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 45:248–260
Kim BK, Kim SU, Kim MJ et al (2013) Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res 19:1503–1511
Tacher V, Lin M, Chao M et al (2013) Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. Acad Radiol 20:446–452
Chapiro JWL, Lin M et al (2014) A radiological-pathological analysis of contrast-enhanced and diffusion-weighted MRI in patients with HCC after TACE – testing the diagnostic accuracy of 3D quantitative image analysis. Radiology 273:746–758
Pellerin O, Lin M, Bhagat N, Ardon R, Mory B, Geschwind JF (2013) Comparison of semi-automatic volumetric VX2 hepatic tumor segmentation from cone beam CT and multi-detector CT with histology in rabbit models. Acad Radiol 20:115–121
Kim S, Mannelli L, Hajdu CH et al (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31:348–355
Wagner M, Doblas S, Daire JL et al (2012) Diffusion-weighted MR imaging for the regional characterization of liver tumors. Radiology 264:464–472
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part III: multivariate data analysis – choosing a model and assessing its adequacy and fit. Br J Cancer 89:605–611
Hipps D, Ausania F, Manas DM, Rose JD, French JJ (2013) Selective interarterial radiation therapy (SIRT) in colorectal liver metastases: how do we monitor response? HPB Surg 2013:570808
Kekelidze M, D'Errico L, Pansini M, Tyndall A, Hohmann J (2013) Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol 19:8502–8514
Koh DM, Brown G, Meer Z, Norman AR, Husband JE (2007) Diagnostic accuracy of rim and segmental MRI enhancement of colorectal hepatic metastasis after administration of mangafodipir trisodium. AJR Am J Roentgenol 188:W154–W161
Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S et al (2013) Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology 266:502–513
Wang Z, Lin M, Lesage D et al (2014) Three-dimensional evaluation of Lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol 21:393–399
Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331
Huppert P, Wenzel T, Wietholtz H (2013) Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol. doi:10.1007/s00270-013-0632-0
Jakobs TF, Hoffmann RT, Dehm K et al (2008) Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 19:1187–1195
Sato KT, Omary RA, Takehana C et al (2009) The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol 20:1564–1569
Fiorentini G, Aliberti C, Mulazzani L et al (2014) Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res 34:575–584
Mahnken AH, Pereira PL, de Baere T (2013) Interventional oncologic approaches to liver metastases. Radiology 266:407–430
Mulcahy MF, Lewandowski RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:1849–1858
Rosenbaum CE, Verkooijen HM, Lam MG et al (2013) Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J Nucl Med 54:1890–1895
Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS (2014) Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol 25:256–265
Acknowledgments
The scientific guarantor of this publication is Jean-François Geschwind. The authors of this manuscript declare relationships with the following companies: JC, grant support: Rolf W. Günther Foundation for Radiological Sciences; RD, none; ML, Philips employee; RS, none; DL, Philips employee; ZW, none; LJS, grant support: Rolf W. Günther Foundation for Radiological Sciences; JFG, consultant: Miocompatibles/BTG, Bayer HealthCare, Guerbet, Nordion/BTG, Philips HealthCare and Jennerex. Grant support: Biocompatibles/BTG, Bayer HealthCare, Philips Medical, Nodion/BTG, Threshold, Guerbet, DOD, NCI-ECOG and NIH-RO1. This study has received funding by NIH/NCI R01 CA160771, P30 CA006973, NCRR UL1 RR 025005, Philips Research North America, Briarcliff Manor, New York and the Rolf W. Günther Foundation for Radiological Sciences. Vivek Charu, Johns Hopkins Bloomberg School of Public Health kindly provided statistical advice for this manuscript.
Institutional review board approval was obtained. Written informed consent was waived by the institutional review board. Methodology: retrospective, diagnostic, prognostic study, performed at one institution.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 21 kb)
Rights and permissions
About this article
Cite this article
Chapiro, J., Duran, R., Lin, M. et al. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol 25, 1993–2003 (2015). https://doi.org/10.1007/s00330-015-3595-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-015-3595-5